2 High-Yield Dividend Stocks That Are Bargain Buys Right Now
Healthcare is a defensive sector that is more resilient to economic downturns than most others. That's one of several reasons it is home to solid dividend stocks, including Pfizer (NYSE: PFE) and Bristol Myers Squibb (NYSE: BMY), two of the leading pharmaceutical companies in the world. In addition to their strong income profiles, both drugmakers look incredibly cheap at their current levels, making them excellent picks.Read on to find out why dividend seekers can confidently add Pfizer and Bristol Myers Squibb to their portfolios.Pfizer has encountered some issues in recent years. Sales of its coronavirus products fell off a cliff, and some of the company's older products are no longer the growth drivers they once were. As a result, the stock has lagged the market, but the sell-off might be a bit overdone. Pfizer's forward price-to-earnings (P/E) ratio of 8.9 looks dirt cheap compared to the healthcare industry's average of 17.2. Pfizer looks attractive at these levels, considering its prospects.Continue reading
Healthcare is a defensive sector that is more resilient to economic downturns than most others. That's one of several reasons it is home to solid dividend stocks, including Pfizer (NYSE: PFE) and Bristol Myers Squibb (NYSE: BMY), two of the leading pharmaceutical companies in the world. In addition to their strong income profiles, both drugmakers look incredibly cheap at their current levels, making them excellent picks.
Read on to find out why dividend seekers can confidently add Pfizer and Bristol Myers Squibb to their portfolios.
Pfizer has encountered some issues in recent years. Sales of its coronavirus products fell off a cliff, and some of the company's older products are no longer the growth drivers they once were. As a result, the stock has lagged the market, but the sell-off might be a bit overdone. Pfizer's forward price-to-earnings (P/E) ratio of 8.9 looks dirt cheap compared to the healthcare industry's average of 17.2. Pfizer looks attractive at these levels, considering its prospects.
